Seeking Alpha

Oral drugs for treating hepatitis C from Merck (MRK) and Abbott Labs (ABT) were highly effective...

Oral drugs for treating hepatitis C from Merck (MRK) and Abbott Labs (ABT) were highly effective in Phase II trials. A regimen that included Merck's MK-5172 suppressed the virus in most patients and appears to be better than the company's Victrelis. Merck now intends to conduct new studies, while Abbott has already started Phase III trials of a regimen of three of its treatments - ABT-450, boosting agent ritonavir (ABT-267) and ABT-333.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs